---
title: "Citi Keeps Their Hold Rating on Arcturus Therapeutics (ARCT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298586306.md"
description: "In a report released yesterday, from Citi maintained a Hold rating on Arcturus Therapeutics, with a price target of $8.00. The company’s shares closed yesterday at $14.74. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arcturus Therapeutics with a $21.33 average price target."
datetime: "2026-09-10T11:05:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298586306.md)
  - [en](https://longbridge.com/en/news/298586306.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298586306.md)
generator: "portal-rs"
---

# Citi Keeps Their Hold Rating on Arcturus Therapeutics (ARCT)

In a report released yesterday, from Citi maintained a Hold rating on Arcturus Therapeutics, with a price target of $8.00. The company’s shares closed yesterday at $14.74.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arcturus Therapeutics with a $21.33 average price target.

### Related Stocks

- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency](https://longbridge.com/en/news/299948643.md)
- [Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)](https://longbridge.com/en/news/297041490.md)
- [These Analysts Slash Their Forecasts On Robinhood After Q3 Results](https://longbridge.com/en/news/303390074.md)
- [BUZZ-PREVIEW: Robinhood climbs as investors eye trading activity](https://longbridge.com/en/news/303253617.md)
- [Vertiv beats Q3 revenue, profit estimates; raises FY guidance](https://longbridge.com/en/news/303371074.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**